Eiger Mountains

Past Events

05/18/16
Speakers will include Dr. Jeffrey Glenn and Dr. Cihan Yurdaydin. Discussions will include an update of LOWR HDV-2 data post-EASL.

New York City, NY,
United States

04/15/16
1) Dahari, H. et al; “Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of the HBV replication.” Poster FRI-111. 2) Dahari, H. et al; “Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.” Poster FRI-115.

Barcelona, Spain,
United States

04/13/16
• Yurdaydin, C. et al; “Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis — results from the on-going LOWR HDV – 2 study.” Oral Presentation, Hepatitis Delta International Network (HDIN) at EASL • Dahari, H. et al; “Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of the HBV replication.” Poster Presentation. • Dahari, H. et al; “Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.” Poster Presentation.
04/13/16
Dr. Cihan Yurdaydin: “Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis — results from the on-going LOWR HDV - 2 study.” Oral; 4:15-4:30 pm

Barcelona, Spain,
United States